Company Presentation – September 2016

This presentation concerning Pluristem Therapeutics may include forward-looking statements whichrepresent Pluristem Therapeutics' expectations or beliefs regarding future events. I caution that suchstatements involve risks and uncertainties that may cause actual results to differ materially from those inthe forward-looking statements. Consequently, all such forward-looking statements are qualified by thecautionary language and risk factors set forth in Pluristem Therapeutics' periodic and other reports filedwith the SEC.

There can be no assurance that the actual results, events or developments referenced in such forward-looking statements will occur or be realized. Pluristem Therapeutics assumes no obligation to updatethese forward-looking statements to reflect actual results, changes in assumptions or changes in factorsaffecting such forward-looking statements.

www.pluristem.com

Forward looking Statement

• Cell therapy (Bio-therapy) company using off-the-shelf, placental-expanded cells to achieve

local and systemic therapeutic effects

Pluristem corporate overview

• Cell therapy company entering late-stage trials for 2 products in 3 indications

• No tissue matching or immunosuppression is required to administer our placenta-derivedcell products

• First in class 3D cell culturing technology allowing for efficient, controlled production ofdifferent cell products in commercial quantities.

Pluristem corporate overview

• Regulatory approval for clinical trials in US, EU, Japan, South Korea, Australia and Israel.

• Public company, Traded in:

• Market Cap: ~ $140 million

• Cash and marketable securities: $33 million (June 30, 2016)

• No debt

• Net burn: ~ $22 million

• No significant royalty liability (other than Israeli government)

• 170 employees (18 PhD, 5 MD)

• IP Ownership: over 75 granted patents and ~135 pending applications

PSTI PSTI/ PLTR

Financial glance

Indication

Critical Limb Ischemia (CLI)*

Femoral Neck Fracture**

Acute Radiation Syndrome (ARS)

Location

U.S.Europe

Japan

U.S./ Europe

U.S.

Pivotal pre-marketing trials

Company Pipeline

Pre-Clinical Phase 2Phase 1 Phase 3 MarketProduct

PLX-PAD

PLX- PAD

PLX- R18

Conditional Approval Pathway

* One Multinational trial- U.S- phase 3, Europe- via adaptive pathway allowing early marketing approval** Pending FDA/EMA approval

Pivotal study via FDA Animal Rule

• 3-4 million people in major pharmaceutical markets*

suffer from CLI (2010)

• Estimated cost for treating CLI is $12 billion per year

• Obstruction of arteries in the leg

• High mortality

• High amputation rates

• Poor treatment options

CLI & Market size

Source: Lifecells LLC

* (U.S., Europe)

Pivotal trial in Japan approved by the PMDA under an accelerated approval pathway

Status of CLI Pivotal Trials

Pivotal Phase III trial design approved by the FDA and planning to submit BLA following single positive pivotal study

Pivotal phase III trial accepted to the Adaptive Pathways project in Europe- only six programs approved worldwide!

U.S / Europe trial- N=250Japan trial- N=75

Accepted to accelerated regulatory pathways by the European and Japanese

regulatory authorities, significantly shortening time to market

Targeting regulatory approval in both U.S. and Europe using data from a

single pivotal Phase III trial in 250 patients

Awarded $8 Million Grant from Europe’s Horizon 2020 Program

Program supported by the Israeli Chief Scientist

CLI Development Plan – Achievements

• Primary endpoint is time to amputation or death

• Other methods of efficacy include: AFS, Quality of life, TcPO2, Pain Score

• Dosing regimen: two doses of 300 million cells, two months apart

• No HLA matching or immunosuppression required

Study Design for U.S. Pivotal Phase 3 Trial (N=250)

• Amputation Free Survival at 6 months:

• US (total n=12) - 100%

• Germany (total n=15) - 93%

• Comparison to published data on no-option CLI:‒ TASC II: 20% death and 40% major amputations in 6m

‒ TAMARIS (n=259 control pts.): 76% AFS in 6m (196/259)

‒ Meta-analyses (Benoit 2011, Weems 2015): 67%-77% AFS at 6m

‒ The majority of events usually occur in the first 6m

Early Clinical Studies Support Design of Pivotal Phase 3 Trial

Pre-Treatment

8 Weeks After Treatment

• Amputation Free Survival at 12 months:

• US (total n=12) - 100%

• Germany (total n=15) - 73%

• Comparison to published data on

no-option CLI:‒ TASC II - (all CLI): 45% AFS, 30% MA &

25% death at 1y‒ Reinecke 2015 - (all CLI): 68% AFS at 1y

R4+R5

Early Clinical Studies Support Design of Pivotal Phase 3 Trial

Additional Supportive Data

Quality of life (VascuQoL) - GermanyQuality of life (VascuQoL) - USA

• Improvement of the quality of life within the first 3m• Higher improvement at 2m repeated dosing• Improvement in quality of life maintained for 12m

Additional Supportive Data

Increase of mean TcPO2 - GermanyIncrease of mean TcPO2 - USA

• Improvement of TcPO2 - after 1 month• Earlier and higher improvement at 2m repeated dosing• Improvement in TcPO2 maintained for 24 months in German study

Additional Supportive Data

Reduction of Pain Score (VAS) - GermanyReduction of Pain Score (VAS) - USA

• Overall pain decrease at month 3 • Most notable decrease with repeated dose

Indication

Critical Limb Ischemia (CLI)

Femoral Neck Fracture**

Acute Radiation Syndrome (ARS)

Location

U.S.Europe*

Japan

U.S./ Europe

U.S.

Pivotal pre-marketing trials

Company Pipeline

Pre-Clinical Phase 2Phase 1 Phase 3 MarketProduct

PLX-PAD

PLX- PAD

PLX- R18

Conditional Approval Pathway

* One Multinational trial- U.S- phase 3, Europe- via adaptive pathway allowing early marketing approval** Pending FDA/EMA approval

Pivotal study via FDA Animal Rule

Muscle Injury following Total Hip Replacement (N=20)

Improvement of 500%

P=0.0067

Change at week 26 in Mean (±SE) Gluteus Medius

MVIC from Day 0 (mITT)

MVIC = Maximum Voluntary Isometric Construction

Orthopedic – Strong clinical data

Muscle Injury following Total Hip Replacement (N=20)

Change in Volume from Day 0

Orthopedic – Strong clinical data

Improvement of 300%

P=0.004

Muscle Injury following Total Hip Replacement (N=20)

Injured (operated) Contralateral(non–operated)

Orthopedic – Strong clinical data

Improvement of 4000%

P=0.012

Indication

Critical Limb Ischemia (CLI)

Femoral Neck Fracture**

Acute Radiation Syndrome (ARS)

Location

U.S.Europe*

Japan

U.S./ Europe

U.S.

Pivotal pre-marketing trials

Company Pipeline

Pre-Clinical Phase 2Phase 1 Phase 3 MarketProduct

PLX-PAD

PLX- PAD

PLX- R18

Conditional Approval Pathway

* One Multinational trial- U.S- phase 3, Europe- via adaptive pathway allowing early marketing approval** Pending FDA/EMA approval

Pivotal study via FDA Animal Rule

Collaboration for ARS with U.S. Government U.S. National Institutes of Health to Support Development of Pluristem's PLX-R18

Collaboration with Fukushima Medical University and Science Center to developPLX-R18 cells for the treatment of other component of ARS (GI, Lung and Skin),

and for morbidities following radiotherapy in cancer patients

Indication

Intermittent Claudication (IC)

Support for Hematopoietic Cell Transplantation

Hematopoietic Cell Transplantation failure

Pulmonary Arterial Hypertension (PAH)

Additional Clinical TrialsCompany Pipeline

Pre-Clinical Phase 2Phase 1 Phase 3 MarketProduct

PLX-PAD

PLX-R18

PLX- R18

PLX-PAD

Cleared for U.S. FDA phase 1 study

• Rich & Diverse• Highly potent

• pro-angiogenic• immunoregulatory

• Young donors• Unlimited source• Easy to collect• Ethically accepted• Over 20,000 Doses of 300

million cells per placenta

The NIH Placenta ProjectLaunched by the U.S. NationalInstitutes of Health (NIH) toFurther explore the role of theplacenta in health and disease.

Placenta derived cells

Culture conditions

PLX-R18Hematological

PLX-PADAngiogenesis

Culture conditions

PLX-CNSNeuronal

PLX-IMMUNEImmunological

Each PLX Product Secretes a Different Range of Proteins to Address Different Varieties of Indications

Culture conditions

Culture conditions

Human placenta- a platform for cell products

Stimulates regeneration of damaged bone marrow to produce blood cells (white, red and platelets)

Reduces inflammation Stimulates growth of collateral blood

vessels Stimulates repair of damaged muscle

3D Manufacturing, in-house cell production150,000 doses annually

CMC & Manufacturing Facility for PLX-PAD approved by FDA,

German, EU, South Korean, Japanese &

Israeli Regulatory Agencies for 3D

culturing for Phase II, III trials and marketing

Late-stage bio-therapy company preparing for 3 pivotal trials

PLX cell products each target different indications with customized cytokine secretion profiles

Low immunogenicity confirmed and NO HLA-MATCHING required• PLX products do not induce in vivo priming of Th1 response • Repeated IM injections of PLX cells from the same placenta do not induce

activation of patients’ memory T-cells• Designed to be used “off-the-shelf” convenience in many medical settings

Key Differentiators

In-house manufacturing with certified batch-to-batch consistency

Proprietary 3D cell production process

CMC & Manufacturing Facility for PLX-PAD approved by FDA and EU Regulators for 3D

culturing for Phase II, III clinical trials and marketing

Key Differentiators

CollaborationsPartner Indication Deal structure

IC, CLISouth Korea only

Joint Venture following marketing authorization bythe South Korean authorities

Acute Radiation Syndrome

U.S. National Institutes of Health (NIH) to SupportDevelopment of PLX-R18

Acute Radiation Syndrome

Pluristem will contribute cells and scientificknowledge, FMU will conduct the studies andprovide the required resources.

Acute Radiation Syndrome

Conducting trials to test PLX-R18 cells in thetreatment of ARS and understanding of MOA

CLI, Immunology,Cardiovascular,

Orthopedic

Research to test the unique immunology of theplacenta and cells MOA

Pluristem keeps IP and manufacturing

rights in all collaborations

Initiate pivotal pre-marketing clinical trials in:

• Critical Limb Ischemia (CLI)-

U.S and Europe- Phase 3 study (N=250)

Japan- pivotal trial (N=75) via Conditional Approval pathway for regenerative medicine

• Acute Radiation Syndrome (ARS) – Large animal study via FDA Animal Rule, funded by the NIH

• Hip Fracture Repair- Entering advanced clinical trials in U.S and Europe subject to regulatory approvals

Complete enrollment In Intermittent Claudication (IC) trial ongoing in U.S, Germany, Israel and South Korea

Patients recruitment for Phase 1 trial in incomplete engraftment of hematopoietic cell transplant cleared by the FDA

Company milestones- 12 months

Unmet MedicalNeed

• Critical Limb Ischemia – limited treatment options• Muscle Injury – need to improve muscle function following

trauma• Damaged or poorly functioning Bone Marrow – ARS, HCT

Significant Market

Opportunity

• CLI – $12 billion global market• Orthopedic indications – broad markets• Hematologic indications – broad markets• Incidence of many indications increasing in aging populations

PLX cells Products

• Off-the-shelf therapy, no tissue matching or immunosuppression• Well-described mechanism of action• Placenta-derived • Convenient for use in most medical settings

Pluristem • Late-stage bio-therapy company preparing for 3 pivotal trials• Primary endpoint met in all completed clinical trials• FDA, EU and Japan – approved manufacturing facility• Highly efficient 3D cell production technology • Broad platform with tailored products• Strong balance sheet & IP

Investment Highlights

Zami AbermanChairman & CEO

Efrat Livne-Hadass VP Human Resources

Racheli Ofir, Ph.D.VP Research & Intellectual Property

Sagi MoranVP Operations

Erez Egozi VP Finance

Karine Kleinhaus, M.D., MPHDivisional VP, North America

Esther Lukasiewicz Hagai, M.D., Ph.D. VP Clinical & Medical Affairs

Lior RavivDirector of Development

Hillit Mannor Shachar, M.D., M.B.A.VP Business Development

Yaky YanayPresident & COO

Orly AmiranVP Quality Assurance

Management team

Thank you!